Clinical Trial: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06948435) titled 'A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1' on April 21.

Brief Summary: GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Hypertension Overweight or Obesity

Intervention: DRUG: Orforglipron

Administered orally

DRUG: Placebo

placebo administered.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Comp...